Wall Street analysts predict that Biopharmx Corp (NYSE:BPMX) will announce sales of $20,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Biopharmx Corp’s earnings, with the lowest sales estimate coming in at $10,000.00 and the highest estimate coming in at $30,000.00. Biopharmx Corp also posted sales of $20,000.00 during the same quarter last year. The firm is scheduled to report its next earnings results on Monday, September 11th.

On average, analysts expect that Biopharmx Corp will report full year sales of $20,000.00 for the current fiscal year, with estimates ranging from $30,000.00 to $590,000.00. For the next financial year, analysts expect that the firm will report sales of $5.07 million per share, with estimates ranging from $50,000.00 to $15.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Biopharmx Corp.

Separately, ValuEngine upgraded Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 24th.

Biopharmx Corp (NYSE BPMX) traded down 2.58% during trading on Friday, hitting $0.34. The stock had a trading volume of 405,423 shares. Biopharmx Corp has a 52 week low of $0.19 and a 52 week high of $0.90. The company’s 50-day moving average is $0.31 and its 200 day moving average is $0.48. The firm’s market cap is $25.20 million.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/09/20000-00-in-sales-expected-for-biopharmx-corp-bpmx-this-quarter.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.